RICHTVXNEWS
A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
CNBC · ENGLEWOOD CLIFFS — Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
- CODE
- RT-A18640
- PUBLISHER
- CNBC
- TOPIC
- Business
- PUBLISHED
- 03 November 2026 · 09:35 UTC
- FIRST SEEN
- 03 November 2026 · 09:45 UTC
- ORIGINAL
- https://www.cnbc.com/2026/11/03/genmab-cancer-drugs-petosemtamab.html
- SHA-256
- aafeaf600dda8031845661a714bce8d741e90902371bf41245156d4726b89944
The fingerprint is the SHA-256 of the original link, the headline and the publication time joined by “|”. Anyone can recompute it to confirm the headline and link were not changed here.
Headline and short excerpt from CNBC, taken from its public news feed. The full story and its photos belong to CNBC — read it at the original. RICHTVX NEWS is an independent aggregator and is not affiliated with CNBC. Corrections: legal@richtvx.news.
More from CNBC
Midterm elections could jolt stocks if Democrats sweep CongressRT-04A171 · BUSINESS
5 things to watch on Election Day as Democrats push for control of CongressRT-DFE469 · BUSINESS
Oil prices climb after U.S. strikes Iran's Qeshm IslandRT-8F1BEF · BUSINESS